Infection and Immunity · 2007 · 103 citations · 32 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyImmune Response To VaccinationMalariaVaccinationVector-based VaccinesViral VaccinesViral Vector VaccinesAdenoviral VectorsAdenovirus VaccinesAdenovirus VectorsBoostingInterferon Gamma ProductionMalaria VaccinesPlasmodium FalciparumTh1 Immune Response
The RTS,S/AS02A protein-based vaccine consistently demonstrates significant protection against infection with Plasmodium falciparum malaria and also against clinical malaria and severe disease in children in areas of endemicity. Here we demonstrate with rhesus macaques that priming with a replication-defective human adenovirus serotype 35 (Ad35) vector encoding circumsporozoite protein (CS) (Ad35.CS), followed by boosting with RTS,S in an improved MPL- and QS21-based adjuvant formulation, AS01B, maintains antibody responses and dramatically increases levels of T cells producing gamma interferon and other Th1 cytokines in response to CS peptides. The increased T-cell responses induced by the combination of Ad35.CS and RTS,S/AS01B are sustained for at least 6 months postvaccination and may translate to improved and more durable protection against P. falciparum infection in humans.
32
The global distribution of clinical episodes of Plasmodium falciparum malaria
Robert W. Snow, Carlos A. Guerra, Abdisalan M. Noor et al. · Nature · 2005 · 2.7K citations · Full text
Veterinary Medicine, Health Sciences, Infectious Diseases +14
Ronald Vogels, David Zuijdgeest, Richard van Rijnsoever et al. · Journal of Virology · 2003 · 471 citations · Full text
Pedro L. Alonso, Jahit Sacarlal, John J. Aponte et al. · The Lancet · 2005 · 410 citations